Applying the uncertainty principle to immunology

Immunotherapy

Volumn 3, Issue 10, 2011, Pages 1127-1128

  Wang, Ena ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOLOGY; DENDRITIC CELL; EDITORIAL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGY; MACROPHAGE; NATURAL KILLER CELL; NEOPLASM; NEUTROPHIL; PRIORITY JOURNAL;

ANIMALS; AUTOIMMUNITY; CELL COMMUNICATION; CELLULAR MICROENVIRONMENT; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INFECTION; INFLAMMATION; NEOPLASMS; RECEPTOR CROSS-TALK;

EID: 80054116462     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.125     Document Type: Editorial

References (20)

1. + T cells in cancer immunotherapy Immunotherapy 2(5) 607 (2010).
2. Shanker A, Verdeil G, Buferne M et al. CD8 T cell help for innate antitumor immunity. J. Immunol. 179, 6651-6662 (2007).
3. Deola S, Panelli MC, Maric D et al. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentaton through CD27-CD70 interactions. J. Immunol. 130, 1362-1372 (2008).
4. Olkhanud PB, Damdinsuren B, Bodogai M et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T regulatory cells. Cancer Res. 71, 3505-3515 (2011).
5. Milne K, Kobel M, Kalloger SE et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA 1 as positive prognostic factors. PLoS ONE 4, E6412 (2009).
6. +) T cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 33, 435-441 (2010).
7. +) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 126, 2635-2643 (2010).
8. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL 10 Trends Immunol. 24, 36-43 (2002).
9. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophage as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002). (Pubitemid 35223554)
10. + cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 113, 3620-3630 (2009).
11. Malhotra A, Shanker A. Natural killer cells: immune cross-talk and therapeutic implications. Immunotherapy (2011) (In Press).
12. Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH. The split personality of NKT cells in malignancy and autoimmune disorders. Immunotherapy (2011) (In Press).
13. Porta C, Ribold E, Totaro MG, Strauss L, Sica A, Mantovani A. Macrophages in cancer and infectious disease: the "good" and the "bad". Immunotherapy (2011) (In Press).
14. Cools N, Petrizzo A, Smits E et al. Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? Immunotherapy (2011) (In Press).
15. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector, and memory CD8 T cells trafficking: parallels and distinctions. Immunotherapy (2011) (In Press).
16. Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Immunotherapy (2011) (In Press).
17. Gorgun G, Anderson KC. Lymphocyte regulation by stromal cell network: implications for Immunotherapy Immunotherapy (2011) (In Press).
18. Lowe DB, Storkus WJ. Chronic inflammation and immunologic-based contraints in malingnant disease. Immunotherapy (2011) (In Press).
19. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 371, 771-783 (2008).
20. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol. 29, 256-262 (2008).